Group 1 - The company announced the successful payment of its third phase of super short-term financing bonds for 2025, ensuring the smooth execution of the payment process [1] - The bond payment will be made to the designated account of the bondholders on the payment date, with adjustments for public holidays [1] - The company emphasizes the importance of timely notification for any changes in the fund transfer path by bondholders to avoid delays in receiving funds [1] Group 2 - The company will hold its first extraordinary general meeting of shareholders in 2026 on February 5, 2026, at 14:00 [5] - Voting will be conducted through a combination of on-site and online methods, with specific time slots for online voting [6][7] - The meeting will discuss various resolutions, including special resolutions and those requiring abstention from related shareholders [9] Group 3 - The company has issued a total of 5 billion RMB in super short-term financing bonds in its second phase for 2026, with funds received on January 19, 2026, to be used for working capital and repaying bank loans [24] - The company has previously issued multiple phases of super short-term financing bonds, with the total amount of outstanding bonds yet to mature [22][23] Group 4 - The company has announced the achievement of conditions for the third release of restrictions on its 2021 stock incentive plan, allowing 324 participants to unlock 4.476712 million shares, representing 0.34% of the total share capital [25][36] - The company has followed all necessary procedures and received approvals for the stock incentive plan, ensuring compliance with relevant regulations [36][37] Group 5 - The company has disclosed its expected daily related transactions for 2026, which will exceed 30 million RMB and require shareholder approval due to the amount exceeding 5% of the latest audited net assets [41][43] - The related transactions are deemed necessary for the company's operations and will be conducted at market prices, ensuring no harm to the company's interests [41][51]
南京医药集团股份有限公司2025年度第三期超短期融资券兑付公告